154 related articles for article (PubMed ID: 9443715)
1. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis.
Lange DJ; Murphy PL; Diamond B; Appel V; Lai EC; Younger DS; Appel SH
Arch Neurol; 1998 Jan; 55(1):93-6. PubMed ID: 9443715
[TBL] [Abstract][Full Text] [Related]
2. Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis.
Jossan SS; Ekblom J; Gudjonsson O; Hagbarth KE; Aquilonius SM
J Neural Transm Suppl; 1994; 41():237-41. PubMed ID: 7931231
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers.
Weinberger AH; Reutenauer EL; Jatlow PI; O'Malley SS; Potenza MN; George TP
Drug Alcohol Depend; 2010 Mar; 107(2-3):188-95. PubMed ID: 19939587
[TBL] [Abstract][Full Text] [Related]
4. An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis.
Mazzini L; Testa D; Balzarini C; Mora G
J Neurol; 1994 Feb; 241(4):223-7. PubMed ID: 8195821
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
Amsterdam JD
J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131
[TBL] [Abstract][Full Text] [Related]
7. [The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trials].
Kwieciński H; Janik P; Jamrozik Z; Opuchlik A
Neurol Neurochir Pol; 2001; 35(1 Suppl):101-6. PubMed ID: 11732275
[TBL] [Abstract][Full Text] [Related]
8. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
Filip V; Kolibás E
J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence.
Elkashef A; Fudala PJ; Gorgon L; Li SH; Kahn R; Chiang N; Vocci F; Collins J; Jones K; Boardman K; Sather M
Drug Alcohol Depend; 2006 Dec; 85(3):191-7. PubMed ID: 16730924
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia.
Bodkin JA; Siris SG; Bermanzohn PC; Hennen J; Cole JO
Am J Psychiatry; 2005 Feb; 162(2):388-90. PubMed ID: 15677608
[TBL] [Abstract][Full Text] [Related]
11. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
Amsterdam JD; Bodkin JA
J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Meininger V; Genge A; van den Berg LH; Robberecht W; Ludolph A; Chio A; Kim SH; Leigh PN; Kiernan MC; Shefner JM; Desnuelle C; Morrison KE; Petri S; Boswell D; Temple J; Mohindra R; Davies M; Bullman J; Rees P; Lavrov A;
Lancet Neurol; 2017 Mar; 16(3):208-216. PubMed ID: 28139349
[TBL] [Abstract][Full Text] [Related]
13. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
Sano M; Ernesto C; Thomas RG; Klauber MR; Schafer K; Grundman M; Woodbury P; Growdon J; Cotman CW; Pfeiffer E; Schneider LS; Thal LJ
N Engl J Med; 1997 Apr; 336(17):1216-22. PubMed ID: 9110909
[TBL] [Abstract][Full Text] [Related]
14. Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS).
Jang S; Jung S; Pae C; Kimberly BP; Craig Nelson J; Patkar AA
J Affect Disord; 2013 Dec; 151(3):854-9. PubMed ID: 24021959
[TBL] [Abstract][Full Text] [Related]
15. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
Bodkin JA; Amsterdam JD
Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221
[TBL] [Abstract][Full Text] [Related]
16. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.
Sacktor N; Schifitto G; McDermott MP; Marder K; McArthur JC; Kieburtz K
Neurology; 2000 Jan; 54(1):233-5. PubMed ID: 10636157
[TBL] [Abstract][Full Text] [Related]
17. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
[TBL] [Abstract][Full Text] [Related]
18. Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial.
Park SB; Vucic S; Cheah BC; Lin CS; Kirby A; Mann KP; Zoing MC; Winhammar J; Kiernan MC
EBioMedicine; 2015 Dec; 2(12):1916-22. PubMed ID: 26844270
[TBL] [Abstract][Full Text] [Related]
19. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation.
George TP; Vessicchio JC; Termine A; Jatlow PI; Kosten TR; O'Malley SS
Biol Psychiatry; 2003 Jan; 53(2):136-43. PubMed ID: 12547469
[TBL] [Abstract][Full Text] [Related]
20. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.
Graf M; Ecker D; Horowski R; Kramer B; Riederer P; Gerlach M; Hager C; Ludolph AC; Becker G; Osterhage J; Jost WH; Schrank B; Stein C; Kostopulos P; Lubik S; Wekwerth K; Dengler R; Troeger M; Wuerz A; Hoge A; Schrader C; Schimke N; Krampfl K; Petri S; Zierz S; Eger K; Neudecker S; Traufeller K; Sievert M; Neundörfer B; Hecht M;
J Neural Transm (Vienna); 2005 May; 112(5):649-60. PubMed ID: 15517433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
